Shares of Dynavax Technologies Co. (NASDAQ:DVAX) have earned an average broker rating score of 1.25 (Strong Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating and three have assigned a strong buy rating to the company. Dynavax Technologies’ rating score has declined by 25% from three months ago as a result of a number of analysts’ ratings changes.
Brokers have set a one year consensus price target of $46.25 for the company and are expecting that the company will post ($0.72) EPS for the current quarter, according to Zacks. Zacks has also assigned Dynavax Technologies an industry rank of 73 out of 265 based on the ratings given to related companies.
A number of research firms have weighed in on DVAX. RBC Capital began coverage on shares of Dynavax Technologies in a research report on Monday, November 30th. They set an “outperform” rating and a $48.00 price objective on the stock. Zacks Investment Research cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Friday, October 30th.
Shares of Dynavax Technologies (NASDAQ:DVAX) opened at 24.16 on Monday. The stock has a 50 day moving average of $25.88 and a 200 day moving average of $26.26. The stock’s market capitalization is $928.35 million. Dynavax Technologies has a 52-week low of $15.80 and a 52-week high of $32.49.
Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.82) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.78) by $0.04. The business had revenue of $1.20 million for the quarter, compared to analyst estimates of $1.65 million. The company’s revenue was down 45.5% on a year-over-year basis. Analysts forecast that Dynavax Technologies will post ($3.29) earnings per share for the current year.
An institutional investor recently bought a new position in Dynavax Technologies stock. Jennison Associates acquired a new position in Dynavax Technologies Co. (NASDAQ:DVAX) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The hedge fund acquired 611,938 shares of the biopharmaceutical company’s stock, valued at approximately $15,017,000. Jennison Associates owned about 1.59% of Dynavax Technologies as of its most recent SEC filing.
Dynavax Technologies Corporation (NASDAQ:DVAX) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The Company’s pipeline of product candidates includes HEPLISAV-B, an investigational adult hepatitis B vaccine, is in Phase III clinical trials; SD-101, a cancer immunotherapy candidate, is in Phase I/II clinical trials; AZD1419, a candidate drug for asthma, is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases, is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.
For more information about research offerings from Zacks Investment Research, visit Zacks.com